Published in Blood Weekly, December 11th, 2003
Scientists in the United States conducted a study "to determine the efficacy of and tolerance to antithymocyte globulin (ATG)-based therapy" in MDS patients.
"Therapy consisted of ATG 40 mg/kg/day daily intravenously (i.v.) for four days; cyclosporine daily orally for 6 months with levels titrated between 200 and 400 mg/dL; and methylprednisone 1 mg/kg i.v. daily before each dose of ATG," explained S. Yazji and coauthors at the University of Texas' M.D. Anderson Cancer Center.
"Of 32 patients treated, 31 patients were evaluable. The median age...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.